<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639457</url>
  </required_header>
  <id_info>
    <org_study_id>DK 049393 (completed)</org_study_id>
    <secondary_id>WU 157</secondary_id>
    <nct_id>NCT00639457</nct_id>
  </id_info>
  <brief_title>Exercise and Pioglitazone for HIV-Metabolic Syndromes</brief_title>
  <official_title>Exercise and Pioglitazone for HIV-Metabolic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d)
      with and without aerobic and strength exercise training for reducing glucose intolerance and
      central adiposity in HIV-infected people. We anticipate that pioglitazone + exercise training
      will improve glucose metabolism and insulin sensitivity, and reduce central adiposity more
      than pioglitazone alone. These improvements should translate into reduced cardiovascular
      disease risk in HIV-infected people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our prior research has examined the pathogenesis and potential treatments for metabolic
      complications in people living with HIV. We have adopted the &quot;lipotoxicity&quot; hypothesis for
      Metabolic Syndrome X to explain the pathogenesis of impaired glucose tolerance (IGT) and fat
      redistribution in HIV: increased lipolysis and mobilization of lipids and free fatty acids
      from subcutaneous adipose depots leads to their excessive deposition in muscle and liver
      which contributes to dyslipidemia, insulin resistance, increased hepatic glucose output, and
      possibly visceral fat accumulation. Effective treatments have not been identified. Consensus
      groups recommend regular exercise and dietary modifications as primary and pharmacologic
      interventions as secondary treatments for the syndromes. We propose to test the efficacy of
      aerobic and weight lifting exercise training and an oral insulin-sensitizing agent
      (pioglitazone) as treatments for HIV-associated IGT and fat redistribution. We propose a
      4-month, 2-group randomized study to evaluate the efficacy of pioglitazone and exercise +
      pioglitazone in 40 men and 40 women living with HIV and IGT and fat redistribution. We will
      measure: insulin sensitivity, glucose disposal rate, hepatic glucose production rate
      (5hr-hyperinsulinemic euglycemic clamp with 6,6-[2H2]-glucose); whole-body and regional fat
      and muscle content (1H-MRI of the abdomen and thigh &amp; DEXA), soleus muscle and liver lipid
      content (1H-MRS), muscle and fat PPARgamma/alpha mRNA and protein expression, serum lipid
      profiles, and serum adiponectin levels before and at the end of 4 months of treatment. We
      hypothesize that exercise training + pioglitazone will be more effective than pioglitazone
      alone at improving insulin sensitivity, reducing visceral fat, liver and muscle lipid
      content, and increasing peripheral subcutaneous fat content in HIV-infected people. We
      hypothesize that combined treatment will be more effective because exercise training will
      activate PPARalpha expression in muscle and pioglitazone will activate PPARy expression in
      fat and muscle. We anticipate that this project will provide direct evidence that supports
      the combined use of exercise training and pioglitazone in people living with HIV and
      experiencing metabolic and anthropomorphic disorders that increase cardiovascular disease
      risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin-stimulated Glucose Disposal Rate</measure>
    <time_frame>Baseline and week16</time_frame>
    <description>Insulin-mediated glucose disposal rate per kg of fat free mass per min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visceral Fat Volume</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Subcutaneous Fat Volume</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Lipid Content</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Glucose Production Rate</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid and Lipoprotein Levels</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzyme Levels</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline and Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Percentage of blood volume that is red cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Adiponectin Levels</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Contractility</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>E/A ratio; ratio of the early (E) to late (A) ventricular filling velocities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Contractility-LV Ejection Time</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>Time required to empty the left ventricle into the aorta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Contractility-DT</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>Deceleration time; time from the peak of early diastolic filling to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Contractility-SBP</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>Systolic blood pressure; peak vascular pressure during ventricular contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Contractility-DBP</measure>
    <time_frame>Baseline and week 16</time_frame>
    <description>Diastolic blood pressure; vascular pressure during ventricular relaxation (diastole)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV Infections</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone + Exercise training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Oral 30mg/day for 16 weeks</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Pioglitazone + Exercise training</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks</description>
    <arm_group_label>Pioglitazone + Exercise training</arm_group_label>
    <other_name>Physical activity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 yr old HIV-infected men (n=40) and women (n=40).

          2. Source documentation of HIV status.

          3. Stable on highly active antiretroviral therapy (HAART) that may or may not include
             HIV-protease inhibitors for at least 3 months prior to enrollment. As of Jan 2005,
             HIV-infected long-term non-progressors will be included, even though they are not
             receiving HAART because it is likely that their disease status will not advance during
             the study period.

          4. Impaired glucose tolerance (IGT) or type 2 diabetes and fat redistribution. IGT is
             defined as: fasting (8hr) plasma glucose 100-126mg/dL or plasma glucose &gt;140 mg/dL
             2-hours after a 75g-oral glucose load. This definition (proposed/revised May 2006)
             includes volunteers with adult onset type 2 diabetes (non-insulin dependent diabetes),
             because we believe that these volunteers may benefit from the potential
             glucose-lowering actions of pioglitazone with or without exercise training. Fat
             redistribution is defined as any 2 of the following: waist-to-hip ratio &gt;0.85 women or
             &gt;0.95 men, or trunk/appendicular adipose ratio using whole-body DEXA &gt;0.85 women or
             &gt;1.3 men, or &lt;15% leg fat (DEXA; (leg fat/total body fat) x100), or visceral adiposity
             VAT &gt;120 cm2 women or &gt;140 cm2 men, or a VAT/TAT ratio &gt;0.30 women or &gt;0.40 men.
             Overall, the eligibility criteria are designed to include subjects with metabolic
             syndromes that increase CVD risk, and the potential to gain the greatest benefit from
             pioglitazone and exercise training. These inclusion criteria will help select/maintain
             homogeneous groups of study participants.

          5. Plasma HIV RNA (Roche Amplicor® assay) &lt;5000 copies/ml OR a CD4 T-cell count &gt;100
             cells/µL and stable for previous 3 months.

          6. BMI 20-40kg/m2.

          7. &quot;Normal&quot; blood chemistries for at least 1 month prior to enrollment; platelet count
             &gt;30,000/mm3, absolute neutrophil count &lt;750/mm3, transaminases &lt;2.5x the upper limit
             of normal (ULN), creatinine &lt;3x ULN, fasting triglycerides &lt;500 mg/dL.

        Exclusion Criteria:

          1. Medications or agents that might alter/impair glucose metabolism (insulin,
             glucocorticoids, corticosteroids, megace) during the 3 months prior to enrollment or
             at any time during enrollment. Volunteers who developed type 2 diabetes after
             HIV-infection or after starting anti-HIV medications, who are receiving insulin
             sensitizers (metformin, meglitinides, alpha-glucosidase inhibitors) or insulin
             secretagogues (sulfonylureas), but still do not have their blood sugars in control
             (defined as IGT above) are eligible.

          2. Abnormal or unstable (for 3 months prior to enrollment) endocrine blood chemistries
             that might otherwise explain insulin resistance. TSH &lt;0.2 or &gt;12µIU/mL, morning
             cortisol &gt;22µg/dL, IGF-1 &lt;115ng/mL, total testosterone &lt;200ng/dL (men) &lt;15ng/dL
             (women). Use of testosterone, ACTH, thyroid hormone, or rhGH replacement to normalize
             low levels is permitted, but must be stable on hormone replacement for 3 months prior
             to enrollment and will not discontinue this replacement during enrollment. Hormone
             replacement cannot be started during treatment.

          3. Allergy or hypersensitivity to thiazolidinediones. Currently taking a
             thiazolidinedione.

          4. Anti-obesity or anorectic medications during the 3 months prior to enrollment or at
             any time during enrollment. Lipid-lowering medications are permitted (fibrate or
             statin), but the subject must be stable on that agent for at least 3 months prior to
             enrollment. Lipid-lowering agents cannot be started during the treatment period.

          5. Chronic hepatitis B infection (HB surface antigen positive). Active hepatitis C
             infection (detectable Hep C RNA). Those who have cleared hepatitis B or C infection
             are eligible. This was revised in May 2006 to better clarify some uncertainties about
             hepatitis and eligibility.

          6. History of serious cardiovascular conditions or NY Heart Association (NYHA) cardiac
             status Class III or IV, (e.g., recent MI, unstable angina, edema, CHF, CAD, CABG,
             valve disease (murmur), stroke, uncontrolled high blood pressure (resting &gt;140/90 mmHg
             on 3 occasions), irregular heart rhythm, bundle-branch block, aortic stenosis, resting
             ST-segment depression &gt;1mm) that would preclude exercise testing/training, or
             substantially increase risk of a CV-event during exercise, or would limit the subjects
             ability to participate in exercise training. Treatment with medications for a
             cardiovascular condition (cardiac glycosides, alpha- or beta-blockers). Some
             antihypertensive medications (Ca++-channel blocker, diuretic, or ACE inhibitor) will
             be permitted.

          7. Insulin-dependent diabetes mellitus (IDDM) or a history of ketoacidosis, symptomatic
             diabetic neuropathy or retinopathy, or renal disease (creatinine &gt;3x ULN).

          8. Hematocrit &lt;34% in men or &lt;25% in women with symptoms (fatigue, &quot;tired-legs&quot;,
             shortness of breath). Hemoglobin &lt;10 gm/100ml with symptoms.

          9. History of eating disorder, significant GI-disease

         10. Nausea, vomiting, diarrhea (&gt;4 loose stools/day) that are unresponsive to treatment
             during 2wks prior to enrollment or that persists for &gt;2wks during enrollment.

         11. Active secondary infection. Any significant change in chronic suppressive therapy for
             an opportunistic infection during the 1-month prior to enrollment.

         12. During the 3 months prior to enrollment, regular aerobic or weight lifting exercise
             training that exceeds the minimum (45min/d, 3d/wk, &gt;75% exercise capacity) required
             for the metabolic, biochemical, and anthropomorphic benefits of exercise to be
             attained as described in the American College of Sports Medicine Guidelines. In Apr
             2006, this exclusion criterion was modified in order to facilitate enrollment of
             volunteers who are moderately-highly active during the 3months prior to screening for
             this study. We will randomize volunteers who exercise regularly into the two treatment
             groups. This will reduce the potential confounding effects of regular exercise on the
             metabolic, biochemical, and anthropomorphic benefits of exercise training that is
             prescribed during the treatment phase. We have excluded several volunteers who are
             regular exercisers, and we believe we may be unnecessarily excluding them. They can be
             included, enrollment will be facilitated, and the study design will not be adversely
             affected, as long as we randomize them into pioglitazone or exercise+pioglitazone
             (1:1).

         13. Unwilling or unable to do supervised exercise 3 sessions/wk at the Medical School
             exercise facility. Any condition that might be contraindicated for exercise training
             (disabling joint, cartilage or muscle injury/disorder that prohibits or severely
             limits participation in regular exercise, disabling arthritis, severe physical
             disabilities, claudication, pulmonary disease, sinus tachycardia, arrhythmias,
             premature atrial or ventricular contractions).

         14. Pregnancy or nursing mothers. Women cannot be pregnant and must agree to use an
             acceptable form of birth control during the treatment period. If birth control pills
             are used, the woman must be stable on these medications for at least 6 months prior to
             enrollment. All metabolic testing will be done in the early follicular phase. Urine
             pregnancy tests (hCG) will be done at baseline and every month the woman is enrolled
             in the study.

         15. Pancreatitis within prior 1 year. Serum triglycerides &gt;500mg/dL esp. with history of
             pancreatitis, or otherwise at high risk for pancreatitis.

         16. Medications that inhibit or slow blood coagulation (ie., blood thinners). Prothrombin
             (clotting) time exceeds 2 sec &gt; control (only in subjects who agree to muscle/fat
             biopsies).

         17. Active malignancy or treatment with chemotherapeutic agents or radiation therapy
             during the 3 months prior to enrollment.

         18. Excessive weight loss (&gt;10% body weight) during the 3 months prior to enrollment.
             History of hyperlactatemia or lactic acidosis, esp. with rapid weight loss.

         19. &quot;Blinded&quot; investigational drugs/medications during the 3 months prior to enrollment
             that will not be unblinded before enrollment. Open-label investigational drugs are
             permitted. Must be stable on these for 3 months prior to enrollment, must remain
             stable on them during the treatment period, and they must be known not to affect
             glucose, lipid, adipose tissue or liver metabolism.

         20. Non-prescription over the counter drugs/supplements that might alter glucose, lipid,
             or adipose tissue metabolism (eg., creatine monohydrate, chromium picolinate, amino
             acid/protein supplements, beta-hydroxy-beta-methyl-butyrate, anabolic-androgenic
             steroids, medium- or long-chain fatty acids, branched chain amino acid supplements,
             amino acids that potentially increase insulin or GH secretion (eg., arginine)) within
             1 month of enrollment. These supplements will not be permitted during the treatment
             period.

         21. Dementia or reduced cognitive function or unable to provide voluntary informed
             consent. Prisoners will not be enrolled.

         22. Active substance abuse (e.g., alcoholism, cocaine, heroin, crack, methamphetamine,
             phencyclidine). Upon evaluation, if the physician-investigator considers that this
             substance abuse does not put the volunteer at risk for an adverse (ie. cardiovascular)
             event, or if the physician-investigator feels that the volunteer will be reliable and
             compliant with the treatment regimens, and that this substance abuse will not
             interfere with the study medications, exercise regimens, or data interpretation, then
             at the physician-investigators discretion the volunteer may be eligible.

         23. Any cytokine or anti-cytokine therapy during the 3 months prior to enrollment.

         24. Patients felt by the Physician Investigator to have uncontrolled hypertension or other
             diseases (i.e. vasculitis, pulmonary HTN) that otherwise may be a cause of significant
             underlying or variable endothelial dysfunction

         25. Receiving vasoactive substances (i.e. nitrates, viagra) other than antihypertensives
             that cannot be discontinued at least 12 hours before endothelial function testing
             (BART).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin E Yarasheski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reeds DN, Cade WT, Mondy K, Bopp C, Lassa-Claxton S, Yarasheski KE. Pioglitazone ± exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance (IGT). Antivir Ther. 12 Suppl 2: L14, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, Bopp C, Lassa-Claxton S, Reeds DN. Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E243-51. doi: 10.1152/ajpendo.00468.2010. Epub 2010 Oct 19.</citation>
    <PMID>20959530</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <results_first_submitted>May 2, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2013</results_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kevin Yarasheski</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>PPAR-gamma agonist</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>inflammation</keyword>
  <keyword>adipose tissue distribution</keyword>
  <keyword>cardiac function</keyword>
  <keyword>vascular function</keyword>
  <keyword>mass spectrometry</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-infected men and women (18 – 60 yr old) were recruited from the AIDS Clinical Trials Unit, the Infectious Diseases Clinic, and the Volunteers for Health Program at Washington University School of Medicine, St. Louis MO between Jan 2005-Dec 2010. Participants were randomly assigned (1:1) to 4 mo of pioglitazone with or without exercise training.</recruitment_details>
      <pre_assignment_details>Exclusion: AIDS diagnosis, non-compliant with anti-HIV medications, unstable CD4+ T-cell count or plasma HIV viremia, illegal drug abuse.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone + Exercise Training</title>
          <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone + Exercise Training</title>
          <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="2"/>
                    <measurement group_id="B2" value="46" spread="2"/>
                    <measurement group_id="B3" value="45" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin-stimulated Glucose Disposal Rate</title>
        <description>Insulin-mediated glucose disposal rate per kg of fat free mass per min</description>
        <time_frame>Baseline and week16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-stimulated Glucose Disposal Rate</title>
          <description>Insulin-mediated glucose disposal rate per kg of fat free mass per min</description>
          <units>µmol glucose/kg FFM/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="4"/>
                    <measurement group_id="O2" value="34" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="6"/>
                    <measurement group_id="O2" value="48" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visceral Fat Volume</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Visceral Fat Volume</title>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1933" spread="150"/>
                    <measurement group_id="O2" value="1890" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1970" spread="164"/>
                    <measurement group_id="O2" value="1746" spread="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Subcutaneous Fat Volume</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Subcutaneous Fat Volume</title>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2101" spread="293"/>
                    <measurement group_id="O2" value="1877" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2164" spread="286"/>
                    <measurement group_id="O2" value="1905" spread="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Lipid Content</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Lipid Content</title>
          <units>percent of water</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="2.0"/>
                    <measurement group_id="O2" value="8.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="2.4"/>
                    <measurement group_id="O2" value="5.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Glucose Production Rate</title>
        <description>ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity</description>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Glucose Production Rate</title>
          <description>ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity</description>
          <units>percent suppression</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="3"/>
                    <measurement group_id="O2" value="37" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="6"/>
                    <measurement group_id="O2" value="42" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Lipid and Lipoprotein Levels</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Lipid and Lipoprotein Levels</title>
          <units>mM/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.3"/>
                    <measurement group_id="O2" value="2.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.3"/>
                    <measurement group_id="O2" value="1.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.2"/>
                    <measurement group_id="O2" value="4.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.2"/>
                    <measurement group_id="O2" value="4.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.2"/>
                    <measurement group_id="O2" value="2.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.1"/>
                    <measurement group_id="O2" value="2.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.05"/>
                    <measurement group_id="O2" value="1.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.05"/>
                    <measurement group_id="O2" value="1.09" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Enzyme Levels</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzyme Levels</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="7"/>
                    <measurement group_id="O2" value="34" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="8"/>
                    <measurement group_id="O2" value="32" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="7"/>
                    <measurement group_id="O2" value="27" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="4"/>
                    <measurement group_id="O2" value="27" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <time_frame>Baseline and Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="0.3"/>
                    <measurement group_id="O2" value="13.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="0.3"/>
                    <measurement group_id="O2" value="13.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit</title>
        <description>Percentage of blood volume that is red cells</description>
        <time_frame>Baseline and Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <description>Percentage of blood volume that is red cells</description>
          <units>% red cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="0.7"/>
                    <measurement group_id="O2" value="40.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="0.7"/>
                    <measurement group_id="O2" value="39.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Adiponectin Levels</title>
        <time_frame>Baseline and week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Adiponectin Levels</title>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline serum adiponectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.8"/>
                    <measurement group_id="O2" value="4.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 serum adiponectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="0.7"/>
                    <measurement group_id="O2" value="6.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Contractility</title>
        <description>E/A ratio; ratio of the early (E) to late (A) ventricular filling velocities</description>
        <time_frame>Baseline and week 16</time_frame>
        <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Contractility</title>
          <description>E/A ratio; ratio of the early (E) to late (A) ventricular filling velocities</description>
          <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline E/A ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.2"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 E/A ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Contractility-LV Ejection Time</title>
        <description>Time required to empty the left ventricle into the aorta</description>
        <time_frame>Baseline and week 16</time_frame>
        <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Contractility-LV Ejection Time</title>
          <description>Time required to empty the left ventricle into the aorta</description>
          <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LV ejection time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296" spread="8"/>
                    <measurement group_id="O2" value="281" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 LV ejection time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" spread="9"/>
                    <measurement group_id="O2" value="305" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Contractility-DT</title>
        <description>Deceleration time; time from the peak of early diastolic filling to baseline</description>
        <time_frame>Baseline and week 16</time_frame>
        <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Contractility-DT</title>
          <description>Deceleration time; time from the peak of early diastolic filling to baseline</description>
          <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline DT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" spread="7"/>
                    <measurement group_id="O2" value="214" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 DT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" spread="6"/>
                    <measurement group_id="O2" value="190" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Contractility-SBP</title>
        <description>Systolic blood pressure; peak vascular pressure during ventricular contraction</description>
        <time_frame>Baseline and week 16</time_frame>
        <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Contractility-SBP</title>
          <description>Systolic blood pressure; peak vascular pressure during ventricular contraction</description>
          <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="2"/>
                    <measurement group_id="O2" value="121" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="2"/>
                    <measurement group_id="O2" value="114" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Contractility-DBP</title>
        <description>Diastolic blood pressure; vascular pressure during ventricular relaxation (diastole)</description>
        <time_frame>Baseline and week 16</time_frame>
        <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone + Exercise Training</title>
            <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Contractility-DBP</title>
          <description>Diastolic blood pressure; vascular pressure during ventricular relaxation (diastole)</description>
          <population>Number of participants for measures of myocardial contractility is less than that for all other measures. These measures were added to the protocol (after ~50% enrollment) after some reports suggested that this drug class (thiazolidinediones) may adversely affect heart function.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="3"/>
                    <measurement group_id="O2" value="68" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" spread="4"/>
                    <measurement group_id="O2" value="61" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>Pioglitazone (Actos; 30mg/day) for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone + Exercise Training</title>
          <description>Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No intervention and exercise training only control groups were not included. Intracellular mechanisms were not explored. Relatively small number of participants taking a variety of anti-HIV medication regimens.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kevin Yarasheski, PhD</name_or_title>
      <organization>Washington Univ Med Sch</organization>
      <phone>3143628173</phone>
      <email>key@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

